Oncopeptides virtuella kapitalmarknadsdag

Programmet

14.00 – 16.00 CET (8:00am-10am EST) 30 november 2020

“Building a Fully Integrated Biotechnology Company”

• Introduction and Strategy for Value Growth – Marty J Duvall, CEO Oncopeptides
• Multiple Myeloma
  “Myeloma remains one of the largest unmet medical needs within hematology”
  o Assistant Professor Joshua Richter, MD. Icahn School of Medicine at Mount Sinai Hospital, New York
• Relapsed refractory multiple myeloma and melflufen – clinical experience with melflufen – Panel discussion
  o Professor Paul Richardson, MD, Dana-Farber Cancer Institute, Boston
  o Associate Professor Maria-Victoria Mateos, MD, PhD, University Hospital, Salamanca
  Moderated by Klaas Bakker, MD, PhD, CMO Oncopeptides
• The clinical development program for melflufen
  “Understanding how melflufen can help patients the most” – Jakob Lindberg, CSO Oncopeptides
• Successfully making the drug available for patients in the US
  Overview of US launch of melflufen – Marty J Duvall, CEO Oncopeptides
• Questions and Answers

Kapitalmarknadsdagen kommer att webbsändas via denna länk: https://tv.streamfabriken.com/oncopeptides-cmd-2020